217 Appendix 87. L.M. Reus: Triangulating Heterogeneity in Dementia (28-09-2021) 88. R. Babapour Mofrad: The use of biofluid biomarkers in dementia: implementation in clinical practice and breaking new grounds (08-10-2021) 89. E.H. Thijssen: Blood-based biomarkers for Alzheimer’s disease: assay development and clinical validation (15-11-2021) (Cum Laude) 90. A.C. Baakman: Innovation in cholinergic enhancement for Alzheimer’s Disease (17-11-2021) 91. I.M.W. Verberk: Blood-based biomarkers for Alzheimer’s disease coming to fruition (08-12-2021) (Cum Laude) 92. J.F. Leijenaar: Streamlining VCI: Heterogeneity and Treatment Response (11-01-22) 93. B.D.C. Boon: Deciphering neuropathological heterogeneity in Alzheimer’s Disease: Beyond plaques and tangles (14-01-2022) 94. E.H. Singleton: The behavioral variant of Alzheimer’s disease: a clinical, neuroimaging and neuropathological perspective (02-06-2022) 95. M. van de Beek: The many faces of dementia with Lewy Bodies: Impact on clinical manifestation, disease burden and disease progression (09-09-2022) 96. W. Pelkmans: Imaging neurodegeneration across the Alzheimer’s disease continuum (03-10-2022) 97. J.L. Ebenau: From subjective to objective cognitive decline – Using biomarkers to understand the earliest stages of Alzheimer’s disease (04-10-2022) A
RkJQdWJsaXNoZXIy MjY0ODMw